INACTIVATION OF HIV

通过细胞输注传播病原体 和蛋白质产品是一个持续的和严重的 问题. 拟议的研究旨在评估两者 病毒灭活的物理和化学方法 在这些产品中。 工艺方法将在以下日期进行初步选择： 杀菌效果的基础对容易量化 病毒，以及恢复完整和功能性红细胞， 血小板和血浆凝血因子。 在承诺 已经确定了方法，它们在灭活 HIV和B型以及非甲型、非B型肝炎病毒将被 分别在组织培养和黑猩猩中进行评估。 最后，演示了一批病毒灭菌的新鲜冰冻血浆， 冷沉淀，红细胞和血小板单位 将制备浓缩物并进行临床评价。 纽约血液中心特别适合 实现这些目标，因为它的广泛研究， 血液传播病毒，其在开发和评价 适用于纯化蛋白的病毒灭活方法 衍生物，因为我们的灵长类动物设施的可用性， 在利比里亚。 该项目将进一步受益于我们的供应， 资源材料;我们的实验室、中试工厂和组件 我们在处理和分析血浆方面的经验 蛋白质和血液成分，并在制备实验和 用于人类治疗的许可生物制剂。

The transmission of pathogenic agents by transfusion of cellular and protein products derived from blood is an ongoing and serious problem. The proposed studies are designed to evaluate both physical and chemical approaches for the inactivation of viruses in these products. Process methods will be selected initially on the basis of sterilization efficacy against easily quantifiable viruses, and of recovery of intact and functioning red cells, platelets, and plasma coagulation factors. After promising approaches have been identified, their efficiency in inactivating HIV and type B and non-A, non-B hepatitis viruses will be evaluated in tissue culture and in chimpanzees, respectively. Finally, demonstration lots of virus sterilized fresh frozen plasma, cryoprecipitate, and units of red blood cell and platelet concentrates will be prepared and evaluated clinically. The New York Blood Center is especially well suited to accomplish these goals because of its extensive research with blood borne viruses, its experience in developing and evaluating methods of virus inactivation applicable to purified protein derivatives, and because of the availability of our primate facility in Liberia. This project will further benefit from our supply of resource material; our laboratory, pilot plant, and components facilities; and our experience in handling and analyzing plasma proteins and blood components and in preparing experimental and licensed biologics for therapeutic use in humans.